1355355-49-5

Upstream product

• 555-96-4 Benzylhydrazine 
• 40876-98-0 sodium 1,4-diethoxy-1,4-dioxobut-2-en-2-olate 
• 20570-96-1 benzylhydrazine dihydrochloride 

Downstream Products

• 1355355-52-0 1-[1-benzyl-5-(benzyloxy)-1H-pyrazol-3-yl]-N-methylmethanamine 
• 1355355-51-9 C₁₈H₁₈N₂O₂ 
• 1355355-53-1 C₂₄H₂₉N₃O₃ 
• 1355356-05-6 C₂₄H₂₈ClN₃O₃ 
• 1355355-48-4 tert-butyl [(1-benzyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)methyl]methylcarbamate 
• 1355355-50-8 C₂₀H₂₀N₂O₃ 

Relevant academic research and scientific papers

Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers

We identified and characterized a series of pyrazole amides as potent, selective Cav3.1-blockers. This series culminated with the identification of pyrazole amides 5a and 12d, with excellent potencies and/or selectivities toward the Cav3.2- and Cav3.3-channels. This compound displays poor DMPK properties, making its use difficult for in vivo applications. Nevertheless, this compound as well as analogous ones are well-suited for in vitro studies.

PYRAZOLE COMPOUND

The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.